MayTech Global Investments LLC Boosts Position in DexCom, Inc. (NASDAQ:DXCM)

MayTech Global Investments LLC lifted its position in DexCom, Inc. (NASDAQ:DXCM) by 53.6% during the third quarter, HoldingsChannel reports. The institutional investor owned 259,257 shares of the medical device company’s stock after purchasing an additional 90,498 shares during the period. DexCom comprises approximately 2.3% of MayTech Global Investments LLC’s holdings, making the stock its 16th biggest holding. MayTech Global Investments LLC’s holdings in DexCom were worth $17,381,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of DXCM. Kennedy Capital Management LLC bought a new position in DexCom in the 1st quarter valued at $1,690,000. B. Riley Wealth Advisors Inc. boosted its stake in DexCom by 132.0% during the first quarter. B. Riley Wealth Advisors Inc. now owns 3,766 shares of the medical device company’s stock valued at $522,000 after buying an additional 2,143 shares during the period. Swedbank AB bought a new stake in DexCom during the first quarter valued at $24,519,000. Cetera Investment Advisers grew its position in DexCom by 76.4% during the first quarter. Cetera Investment Advisers now owns 106,881 shares of the medical device company’s stock worth $14,824,000 after buying an additional 46,297 shares in the last quarter. Finally, Cetera Advisors LLC increased its stake in DexCom by 593.4% in the 1st quarter. Cetera Advisors LLC now owns 40,808 shares of the medical device company’s stock worth $5,660,000 after acquiring an additional 34,923 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

DXCM has been the subject of several recent analyst reports. StockNews.com lowered DexCom from a “buy” rating to a “hold” rating in a report on Saturday, November 2nd. Piper Sandler reissued an “overweight” rating and issued a $90.00 price target on shares of DexCom in a research note on Monday, August 26th. Raymond James lowered their price objective on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a research report on Friday, October 25th. Stifel Nicolaus upped their target price on shares of DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday, August 23rd. Finally, JPMorgan Chase & Co. raised their price target on DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a research report on Friday, October 25th. Seven investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, DexCom currently has an average rating of “Moderate Buy” and a consensus target price of $104.59.

DexCom Stock Performance

Shares of NASDAQ:DXCM opened at $78.10 on Thursday. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. The company has a 50-day moving average price of $71.11 and a 200-day moving average price of $88.51. The company has a market cap of $30.51 billion, a price-to-earnings ratio of 46.77, a price-to-earnings-growth ratio of 2.38 and a beta of 1.17. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00.

Insider Activity at DexCom

In other DexCom news, COO Jacob Steven Leach sold 746 shares of the company’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the transaction, the chief operating officer now directly owns 264,915 shares in the company, valued at approximately $18,318,872.25. This represents a 0.28 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Sadie Stern sold 4,259 shares of DexCom stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the sale, the executive vice president now directly owns 71,192 shares in the company, valued at $5,320,178.16. The trade was a 5.64 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 5,431 shares of company stock worth $399,319 in the last 90 days. Company insiders own 0.30% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.